Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 8, 2006, Pages 2109-2112

  Jiang, Tao ^a   Kuhen, Kelli L ^a   Wolff, Karen ^a   Yin, Hong ^a   Bieza, Kimberly ^a   Caldwell, Jeremy ^a   Bursulaya, Badry ^a   Tuntland, Tove ^a   Zhang, Kanyin ^a   Karanewsky, Donald ^a   He, Yun ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

AIDS; Heterocycle; HIV; Inhibitor; Oxindole; Reverse transcriptase; SAR

Indexed keywords

INDOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; INDOLES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33644795609     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.01.066     Document Type: Article

References (12)

1. M. St. Clair, J.L. Martin, G. Tudor-Williams, M.C. Bach, C.L. Vavro, D.M. King, P. Kellam, S.D. Kemp, and B.A. Larder Science 253 1991 1557
2. J. Sebastian, and H. Faruki Med. Res. Rev. 24 2004 115
3. M. Gotte Exert Rev. Anti-Infect. Ther. 2 2004 707
4. M.J. Mugavero, and C.B. Hicks Drug Discovery Today: Ther. Strategies 1 2004 529
5. S. Rusconi, S. La Seta Catamancio, P. Citterio, E. Bulgheroni, S. Kurtagic, M. Galazzi, F. Croce, M. Moroni, and M. Galli Antiviral Ther. 6 2001 41
6. V. Miller, M. Ait-Khaled, C. Stone, P. Griffin, D. Mesogiti, A. Cutrell, R. Harrigan, S. Staszewski, C. Katlama, G. Pearce, and M. Tisdale AIDS 14 2000 163
7. R. Pauwels Curr. Opin. Pharmacol. 4 2004 437
8. L.T. Bacheler Drug Res. Updates 2 1999 56
9. T. Jiang, K.L. Kuhen, K. Wolff, H. Yin, K. Bieza, J. Caldwell, B. Bursulaya, T.Y.-H. Wu, and Y. He Bioorg. Med. Chem. Lett. 16 2006 0000
10. 50 values.
11. All compounds reported are racemic, and only one enantiomer is shown. Data are based on the measurement of the racemic mixture.
12. Flexible docking was conducted using Glide 2.0 (Schrodinger, Inc., Portland, OR, 2002). The protein coordinates were taken from protein databank (pdb code 1FK9).